TrialCirculation2025

Intensive Lowering of LDL Cholesterol Levels With Evolocumab in Autoimmune or Inflammatory Diseases: An Analysis of the FOURIER Trial.

Andre Zimerman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.